|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Talwalkar JA and Gores GJ: Diagnosis and
staging of hepatocellular carcinoma. Gastroenterology. 127(Suppl
1): S126–S132. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ito Y: Oncogenic potential of the RUNX
gene family: 'overview'. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Hao L, Wu J, Zhang J and Su J:
Linarin promotes osteogenic differentiation by activating the
BMP-2/RUNX2 pathway via protein kinase A signaling. Int J Mol Med.
37:901–910. 2016.PubMed/NCBI
|
|
6
|
Ozaki T, Nakamura M and Shimozato O: Novel
implications of DNA damage response in drug resistance of malignant
cancers obtained from the functional interaction between p53 family
and RUNX2. Biomolecules. 5:2854–2876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sugimoto H, Nakamura M, Yoda H, Hiraoka K,
Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H and Ozaki T:
Silencing of RUNX2 enhances gemcitabine sensitivity of
p53-deficient human pancreatic cancer AsPC-1 cells through the
stimulation of TAp63-mediated cell death. Cell Death Dis.
6:e19142015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wysokinski D, Blasiak J and Pawlowska E:
Role of RUNX2 in breast carcinogenesis. Int J Mol Sci.
16:20969–20993. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shrivats AR, McDermott MC, Klimak M,
Averick SE, Pan H, Matyjaszewski K, Mishina Y and Hollinger JO:
Nanogel-mediated RNAi against Runx2 and Osx inhibits osteogenic
differentiation in constitutively active BMPR1A osteoblasts. ACS
Biomater Sci Eng. 1:1139–1150. 2015. View Article : Google Scholar
|
|
10
|
Fujita T, Azuma Y, Fukuyama R, Hattori Y,
Yoshida C, Koida M, Ogita K and Komori T: Runx2 induces osteoblast
and chondrocyte differentiation and enhances their migration by
coupling with PI3K-Akt signaling. J Cell Biol. 166:85–95. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akech J, Wixted JJ, Bedard K, van der Deen
M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR,
Altieri DC, et al: Runx2 association with progression of prostate
cancer in patients: Mechanisms mediating bone osteolysis and
osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010.
View Article : Google Scholar :
|
|
12
|
Baniwal SK, Khalid O, Gabet Y, Shah RR,
Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA and Frenkel B:
Runx2 transcriptome of prostate cancer cells: Insights into
invasiveness and bone metastasis. Mol Cancer. 9:2582010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brusgard JL, Choe M, Chumsri S, Renoud K,
MacKerell AD Jr, Sudol M and Passaniti A: RUNX2 and TAZ-dependent
signaling pathways regulate soluble E-cadherin levels and
tumorsphere formation in breast cancer cells. Oncotarget.
6:28132–28150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sancisi V, Borettini G, Maramotti S,
Ragazzi M, Tamagnini I, Nicoli D, Piana S and Ciarrocchi A: Runx2
isoform I controls a panel of proinvasive genes driving
aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol
Metab. 97:E2006–E2015. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mendoza-Villanueva D, Deng W,
Lopez-Camacho C and Shore P: The Runx transcriptional co-activator,
CBFbeta, is essential for invasion of breast cancer cells. Mol
Cancer. 9:1712010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pratap J, Javed A, Languino LR, van Wijnen
AJ, Stein JL, Stein GS and Lian JB: The Runx2 osteogenic
transcription factor regulates matrix metalloproteinase 9 in bone
metastatic cancer cells and controls cell invasion. Mol Cell Biol.
25:8581–8591. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Selvamurugan N, Kwok S and Partridge NC:
Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth
factor-beta1-stimulated collagenase-3 expression in human breast
cancer cells. J Biol Chem. 279:27764–27773. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edwards H, Xie C, LaFiura KM, Dombkowski
AA, Buck SA, Boerner JL, Taub JW, Matherly LH and Ge Y: RUNX1
regulates phosphoinositide 3-kinase/AKT pathway: Role in
chemotherapy sensitivity in acute megakaryocytic leukemia. Blood.
114:2744–2752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tandon M, Chen Z, Othman AH and Pratap J:
Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth,
survival and sensitivity towards metformin in breast cancer bone
metastasis. Oncogene. Jan 25–2016.Epub ahead of print. View Article : Google Scholar
|
|
20
|
Sancisi V, Gandolfi G, Ragazzi M, Nicoli
D, Tamagnini I, Piana S and Ciarrocchi A: Cadherin 6 is a new RUNX2
target in TgF-β signalling pathway. PLoS One. 8:e754892013.
View Article : Google Scholar
|
|
21
|
van der Deen M, Akech J, Wang T,
Fitzgerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ,
Stein JL and Stein GS: The cancer-related Runx2 protein enhances
cell growth and responses to androgen and TGFbeta in prostate
cancer cells. J Cell Biochem. 109:828–837. 2010.PubMed/NCBI
|
|
22
|
Zeng H and Xu X: RUNX2 RNA interference
inhibits the invasion of osteosarcoma. Oncol Lett. 9:2455–2458.
2015.PubMed/NCBI
|
|
23
|
Peng B, Zhu H, Klausen C, Ma L, Wang YL
and Leung PC: GnRH regulates trophoblast invasion via
RUNX2-mediated MMP2/9 expression. Mol Hum Reprod. 22:119–129. 2016.
View Article : Google Scholar
|
|
24
|
Cohen-Solal KA, Boregowda RK and Lasfar A:
RUNX2 and the PI3K/AKT axis reciprocal activation as a driving
force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tandon M, Chen Z and Pratap J: Runx2
activates PI3K/Akt signaling via mTORC2 regulation in invasive
breast cancer cells. Breast Cancer Res. 16:R162014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niu DF, Kondo T, Nakazawa T, Oishi N,
Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor
Runx2 is a regulator of epithelial-mesenchymal transition and
invasion in thyroid carcinomas. Lab Invest. 92:1181–1190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Akech J, Browne G, Russell S,
Wixted JJ, Stein JL, Stein GS and Lian JB: Runx2-Smad signaling
impacts the progression of tumor-induced bone disease. Int J
Cancer. 136:1321–1332. 2015. View Article : Google Scholar :
|
|
28
|
Chimge NO, Baniwal SK, Little GH, Chen YB,
Kahn M, Tripathy D, Borok Z and Frenkel B: Regulation of breast
cancer metastasis by Runx2 and estrogen signaling: The role of
SNAI2. Breast Cancer Res. 13:R1272011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zaidi SK, Sullivan AJ, van Wijnen AJ,
Stein JL, Stein GS and Lian JB: Integration of Runx and Smad
regulatory signals at transcriptionally active subnuclear sites.
Proc Natl Acad Sci USA. 99:8048–8053. 2002. View Article : Google Scholar : PubMed/NCBI
|
